IMPACTMF PHASE 3


Associated tags: Patient, Pharmacokinetics, JAK, Safety, Imetelstat, Research, New Drug Application, Geron Corporation, FDA, MF, Webcast, Clinical trial, Biotechnology, MDS, Corporation, Depreciation, Health, Pharmaceutical, Clinical Trials, IMPRESS, Pharmaceutical industry, GAAP

Geron Corporation Reports Business Highlights and Fourth Quarter and Full Year 2023 Financial Results

Retrieved on: 
Wednesday, February 28, 2024
Biotechnology, General Health, Pharmaceutical, Health, Janus, Hercules, BAT, European Commission, EMA, Marketing, Research, New Drug Application, Anemia, Transfusion-dependent anemia, Syndrome, MAA, MF, FDA, Geron Corporation, Imetelstat, Exercise, PDUFA, Loan, Risk, Primary myelofibrosis, Society, MDS, Civil service commission, JAK, History, European Medicines Agency, Webcast, Register, SVB, Patient, Federal, Clinical trial, Corporation, NDA, Depreciation

Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company developing investigational first-in-class telomerase inhibitor, imetelstat, to treat hematologic malignancies, today reported business highlights and financial results for the fourth quarter and full year 2023.

Key Points: 
  • Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company developing investigational first-in-class telomerase inhibitor, imetelstat, to treat hematologic malignancies, today reported business highlights and financial results for the fourth quarter and full year 2023.
  • The FDA assigned a Prescription Drug User Fee Act (PDUFA) action date of June 16, 2024 to the NDA.
  • In September 2023, the European Medicines Agency (EMA) validated the Marketing Authorization Application (MAA) for imetelstat in the same proposed indication as the NDA.
  • Geron will host a conference call at 8:00 am ET on Wednesday, February 28, 2024, to discuss business updates and fourth quarter and full year 2023 financial results.

Geron Corporation Reports Business Highlights and Second Quarter 2023 Financial Results

Retrieved on: 
Thursday, August 3, 2023
Health, Clinical Trials, Research, Pharmaceutical, Science, Biotechnology, Ruxolitinib, Employment, EAP, General counsel, Amgen, BeiGene, New Drug Application, Clinical trial, GAAP, MF, ASCO, MDS, Imetelstat, Corporation, Geron Corporation, Patient, Risk, Celgene, EHA, Webcast, Depreciation, FDA, IMPRESS, Fatigue, Novartis, Pharmaceutical industry, Cryptocurrency, Rare-earth element

Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company developing a first-in-class telomerase inhibitor, imetelstat, to treat hematologic malignancies, today reported business highlights and financial results for the second quarter of 2023.

Key Points: 
  • Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company developing a first-in-class telomerase inhibitor, imetelstat, to treat hematologic malignancies, today reported business highlights and financial results for the second quarter of 2023.
  • Initiated Expanded Access Protocol (EAP) in June 2023, making imetelstat available to clinicians and patients prior to potential FDA approval.
  • In the second quarter of 2023, the Company received $17.8 million upon the cash exercise of outstanding warrants.
  • ET on Thursday, August 3, 2023 to discuss business updates, and second quarter financial results.

Geron Corporation Reports Third Quarter 2022 Financial Results and Upcoming Expected Milestones

Retrieved on: 
Thursday, November 3, 2022
Health, Other Science, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Patient, MDS, LR, MF, Company, Lymphatic system, Private Securities Litigation Reform Act, Xi, Exercise, Research, Prejudice, Corporation, Imetelstat, XV, GAAP, RBC, Microdeletion syndrome, Apoptosis, FDA, Intellectual property, Safety, 100,000, Webcast, Pharmacokinetics, U.S. Securities and Exchange Commission, IMPRESS, Geron Corporation, Nasdaq, COVID-19, Agreement, Income, TI, Review, ESA, Clinical trial, Fast Track, New Drug Application, Risk, Jaki, Disease, Security (finance), Insurance, JAK, Depreciation, Fault, Nobel Prize, Pharmaceutical industry, Life insurance, Video game, EU

Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company developing a first-in-class telomerase inhibitor, imetelstat, to treat hematologic malignancies, today reported financial results for the third quarter of 2022 and upcoming expected milestones.

Key Points: 
  • Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company developing a first-in-class telomerase inhibitor, imetelstat, to treat hematologic malignancies, today reported financial results for the third quarter of 2022 and upcoming expected milestones.
  • ET on Thursday, November 3, 2022 to review recent events and third quarter 2022 financial results.
  • This projected non-GAAP financial measure is in addition to, not a substitute for, or superior to, measures of financial performance projected in accordance with GAAP.
  • Geron encourages investors to carefully consider the Companys results under GAAP, as well as the supplemental non-GAAP financial information, to more fully understand Gerons business.

Geron Corporation Reports Second Quarter 2022 Financial Results

Retrieved on: 
Thursday, August 11, 2022
Oncology, Health, Genetics, Clinical Trials, Pharmaceutical, Biotechnology, MDS, Imetelstat, FDA, Telephone, Apoptosis, Intellectual property, U.S. Securities and Exchange Commission, Exercise, Risk, XV, TI, Private Securities Litigation Reform Act, Microdeletion syndrome, Clinical trial, Silicon, Disease, Lymphatic system, Achievement, Xi, Security (finance), Research, Geron Corporation, Income, Silicon Valley Bank, Review, Patient, Company, COVID-19, Depreciation, MF, RBC, Corporation, JAK, Safety, GAAP, Â, Webcast, Insurance, IMPRESS, Ruxolitinib, Nasdaq, Fast Track, 100,000, ID, New Drug Application, ESA, Pharmacokinetics, Pharmaceutical industry, Bank, Lithium, Health insurance, Life insurance, Video game, EU

Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company developing a first-in-class telomerase inhibitor, imetelstat, to treat hematologic malignancies, today reported financial results for the second quarter of 2022 and key upcoming expected milestones.

Key Points: 
  • Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company developing a first-in-class telomerase inhibitor, imetelstat, to treat hematologic malignancies, today reported financial results for the second quarter of 2022 and key upcoming expected milestones.
  • Assuming positive top-line results, U.S. and EU regulatory submissions are also planned in the first and second half of 2023, respectively.
  • ET on Thursday, August 11, 2022 to review recent events and second quarter 2022 financial results.
  • Geron encourages investors to carefully consider the Companys results under GAAP, as well as the supplemental non-GAAP financial information, to more fully understand Gerons business.